Andrew Ambrosy to Neprilysin
This is a "connection" page, showing publications Andrew Ambrosy has written about Neprilysin.
Connection Strength
2.532
-
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. J Am Coll Cardiol. 2020 09 01; 76(9):1034-1048.
Score: 0.747
-
The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions. Eur J Heart Fail. 2018 06; 20(6):963-972.
Score: 0.627
-
Angiotensin receptor-neprilysin inhibitor therapy in heart failure: An end that justifies the means. Am Heart J. 2018 05; 199:176-177.
Score: 0.626
-
Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. JACC Heart Fail. 2020 10; 8(10):859-866.
Score: 0.187
-
Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. JAMA Cardiol. 2020 02 01; 5(2):202-207.
Score: 0.179
-
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 02 07; 380(6):539-548.
Score: 0.165